In addition, several preclinical studies in SLE patients showed antigen-specific Treg cell engineering as a promising therapy for suppressing SLE, such as using the Smith (Sm) autoantigen specific TCR-Tregs (188) and anti-CD19 CAR-Tregs overexpressing Foxp3 (189). The gene discussed is FOXP3; the disease is systemic lupus erythematosus.